Hell No We Won't Go! - User contributions [en]

Foods That Can Increase GLP-1 Hormone

2026-09-14T08:04:20Z

ElaineSams264: Created page with " With so much recent buzz about semaglutide medications, you’ve probably heard about glucagon-like peptide-1 (GLP-1) hormone. [https://projectultimauo.com/PUwiki/index.php/Revolutionizing_Weight_Loss:_The_Impact_Of_GLP-1_Medications Medic GLP Supplement]-1 plays many roles in the body that affect appetite and blood sugar control. While medications that mimic GLP-1 can be extremely helpful for weight loss and managing type 2 diabetes, there are also ways to boost the..."

With so much recent buzz about semaglutide medications, you’ve probably heard about glucagon-like peptide-1 (GLP-1) hormone. [https://projectultimauo.com/PUwiki/index.php/Revolutionizing_Weight_Loss:_The_Impact_Of_GLP-1_Medications Medic GLP Supplement]-1 plays many roles in the body that affect appetite and blood sugar control. While medications that mimic GLP-1 can be extremely helpful for weight loss and managing type 2 diabetes, there are also ways to boost the release of this hormone through diet. Read on to learn what foods to eat to naturally increase GLP-1 levels. These tips are helpful for anyone interested in improving food choices, whether you’re following a diabetic diet meal plan, taking semaglutide, or just [https://www.google.com/search?q=curious curious] about how to eat well. GLP-1 is a hormone, or chemical messenger, that gets released during digestion. In addition to other signals, the presence of fiber, protein, or [https://www.brandsreviews.com/search?keyword=healthy%20fats healthy fats] triggers its release from cells in the small intestine and colon. Next, GLP-1 binds to receptors in the pancreas and stimulates the release of the hormone insulin. Insulin moves sugar that comes from the breakdown of food out of the blood and into cells that need it. GLP-1 also inhibits the production of glucagon from the pancreas. This hormone tells the body to release sugar stored in the liver when blood sugar is low. In addition to lowering blood sugar levels through these mechanisms, GLP-1 slows down stomach emptying. This leads to feelings of fullness and decreased appetite. Finally, some research suggests that GLP-1 may also influence processes in the brain in a way that limits cravings and overeating. Medications that act like GLP-1 receptor agonists, such as semaglutide, are designed to mimic the functions of GLP-1 in the body. They activate GLP-1 receptors, promoting insulin secretion while also inhibiting glucagon secretion from the pancreas. As a result, semaglutide is very effective at improving insulin sensitivity and blood sugar control. Plus, it mimics the other effects of GLP-1 that lead to decreased appetite and subsequent reduced energy intake and weight loss. Want to support your GLP-1 levels through what you eat? Foods high in protein, fiber, and healthy fats can naturally support GLP-1 - but putting that into practice consistently is where most people struggle. Having meals that are already balanced and portioned makes that much easier. We deliver fresh to your door throughout Minnesota, Wisconsin, Illinois, Iowa, Nebraska, North Dakota, South Dakota, and Kansas City. Certain nutrients are responsible for some GLP-1 stimulation in the body. For example, soluble fiber is a type of carbohydrate that does not get digested but can be fermented into short chain fatty acids (SCFAs). These fatty acids have been shown to increase GLP-1 secretion in the colon. Fatty acids from dietary fats may also boost GLP-1 release. In particular, research suggests that unsaturated long-chain fatty acids like those found in olive oil lead to higher blood levels of GLP-1 compared to saturated fatty acids in butter. Alpha-linolenic acid (ALA) and docosahexaenoic acid (DHA), polyunsaturated omega-3 fatty acids found in flaxseed oil and fish, also increase GLP-1 and lower blood sugar. Finally, some amino acids that come from the breakdown of dietary proteins may bind to receptors that stimulate GLP-1 secretion. This may help explain why protein is often considered one of the most satiating nutrients. Just as healthy food choices may increase GLP-1 levels, [https://kunjinmotors.com/bbs/board.php?bo_table=free&wr_id=863323 MedicGLP Official Support] so can exercise. Studies suggest that physical activity can raise GLP-1 to levels that remain even after 24 hours have passed. It’s unclear what kinds of activity are best at boosting GLP-1, but high-intensity exercises such as running may be particularly beneficial. The nutrients that help stimulate GLP-1 secretion are typically found in healthy foods included in dietary guidelines. High-fiber foods, healthy fats, and proteins are the backbone of eating patterns geared towards weight loss and overall health. However, not all foods are created equal when it comes to increasing the release of GLP-1. Specifically, fermentable fibers, unsaturated fatty acids, and lean proteins are key to stimulating the release of this hormone. Timing of meals and other eating habits may also influence GLP-1 levels. Several studies have found that eating carbohydrates later in a meal and consuming protein-rich foods first may increase GLP-1 secretion.

Diabetes Drugs And Weight Loss

2026-09-14T07:05:23Z

ElaineSams264: Created page with " GLP-1 agonists for type 2 diabetes are generally taken by a shot, also called an injection. Most are taken once a day or once a week. GLP-1 agonists include the following medicines. Exenatide extended release (Bydureon BCise). Another form of semaglutide is available in a pill that's taken by mouth once a day. The brand name of that medicine is Rybelsus. Tirzepatide (Mounjaro) is a similar kind of [https://www.fool.com/search/solr.aspx?q=medicine medicine] called a d..."

GLP-1 agonists for type 2 diabetes are generally taken by a shot, also called an injection. Most are taken once a day or once a week. GLP-1 agonists include the following medicines. Exenatide extended release (Bydureon BCise). Another form of semaglutide is available in a pill that's taken by mouth once a day. The brand name of that medicine is Rybelsus. Tirzepatide (Mounjaro) is a similar kind of [https://www.fool.com/search/solr.aspx?q=medicine medicine] called a dual-acting GLP-1/GIP agonist. It's also used to control blood sugar and can support weight loss. It is taken once a week by a shot. All GLP-1 agonists can help with weight loss. But the amount of weight loss depends on the type of medicine and the dose. In general, studies have found that tirzepatide and semaglutide are the most effective for weight loss. Dulaglutide and liraglutide also have been found to be very effective. Other GLP-1 agonists appear to be somewhat less effective for weight loss. But people who take them still have better weight loss results than those who do not take the medicine. GLP-1 agonists mimic the way a hormone called glucagon-like peptide 1 works in the body. When blood sugar starts to rise after a person eats, these medicines cause the body to make more insulin. The extra insulin helps lower blood sugar. Lower blood sugar helps control type 2 diabetes. But it's not clear exactly how GLP-1 agonists lead to weight loss. They appear to curb hunger. They also slow the movement of food from the stomach into the small intestine. That means you may feel full faster and longer, so you eat less. As with any medicine, [https://www.xn--3dkvalq0cx455coz1c.com/wiki/index.php/%E5%88%A9%E7%94%A8%E8%80%85:SamWooldridge13 MedicGLP] there is a risk of side effects when taking a GLP-1 agonist. Some side effects can be serious. More common side effects often improve after taking the medicine for a while. Low blood sugar is a more serious risk linked to GLP-1 agonists. The medical term for that condition is hypoglycemia. But the risk of low blood sugar typically only goes up when a person also is taking another medicine that's known to lower blood sugar. Examples include sulfonylureas and insulin. Have had medullary thyroid cancer or who have a family history of the disease. Have had multiple endocrine neoplasia or who have a family history of the disease. Are pregnant or are actively trying to get pregnant. Certain GLP-1 agonists may not be appropriate for people who have a health condition that affects the intestines, such as gastroparesis, or for [https://veretium.com/dwainm58998299/medicglp-weight-support6528/wiki/Health+Effects+of+Low-Carbohydrate+Diets%3A+where+should+new+Research+Go%3F.- MedicGLP weight support] people who have some types of kidney disease. Studies have linked GLP-1 agonists with certain thyroid tumors in rats. But until more long-term studies are done, the risk to humans isn't known. Science continues to prove that the old adage "you are what you eat" is profoundly true. This is because you have trillions of microorganisms living in your gut, which are directly responsible for nearly every aspect of your health. These microbes make up what’s called your "gut microbiota." They are especially influential in determining your likelihood of gaining excessive [https://bbclinic-kr.com:443/nose/nation/bbs/board.php?bo_table=E05_4&wr_id=1111240 MedicGLP weight support], becoming obese, and [http://www.leelco.com/bbs/board.php?bo_table=free&wr_id=34104 Medic GLP Website] developing obesity-related diseases like diabetes, heart disease, and premature death. The gut microbiome (the expressed genes of your gut microbiota) plays a major role in your metabolism through energy production, storage, and expenditure. So, it’s no surprise that science has found a strong connection between gut microbiome imbalance and metabolic syndrome. Yikes! If you have the wrong mix of microbes, it could be making it tough for you to get your health on track! Did you know: Scientists can actually look at your gut microbiome composition and tell with 90% accuracy if you are obese or lean. That’s pretty impressive, isn’t it? 1. Unable to lose weight and keep it off? 2. Struggling to fight cravings? 3. Sick of starving yourself for weight loss? 4. Baffled as to why no diet seems to really work for you? Depending on the composition of your gut microbiome, your microbes can either boost your health or weigh you down (figuratively and literally). The good news is this: You have control over these little guys with every bite you eat. Diet has the power to change the landscape of your gut microbiome. So, if you’ve tried multiple diets and can’t seem to get the results you want, it’s time to look into your gut microbiome.Will You Lose Weight Naturally on an Individualized Diet? If you’ve been struggling to lose weight and keep it off - it could be your gut microbiome. While Viome doesn’t guarantee weight loss, it has been an exciting result many of our customers have reported. "Fiona’s update day 37!

Outdated Boomer Diet Trends That Actually Deserve A Comeback

2026-09-14T06:10:30Z

ElaineSams264: Created page with " When you think of boomer weight-management strategies, your mind might automatically picture smack-my-head fads like the grapefruit or cabbage soup diets. Yet not all boomer dieting trends were off-base, offbeat, or just plain awful. In fact, some eating behaviors probably deserve a second chance among modern audiences. This doesn't mean you should run out, buy a cookbook from the '50s, '60s, or '70s, and go full vintage with your kitchen activities. A 2015 study in..."

When you think of boomer weight-management strategies, your mind might automatically picture smack-my-head fads like the grapefruit or cabbage soup diets. Yet not all boomer dieting trends were off-base, offbeat, or just plain awful. In fact, some eating behaviors probably deserve a second chance among modern audiences. This doesn't mean you should run out, buy a cookbook from the '50s, '60s, or '70s, and go full vintage with your kitchen activities. A 2015 study in The Milbank Quarterly found that boomers aren't necessarily healthier than later generations due to a general rise in obesity, among other factors. According to a 2024 study in the International Journal of Environmental Research and Public Health, obesity levels have consistently risen since 1959 (1946 marked the start of the boomer generation). With that said, you might want to rethink the way you eat or exercise when you hear about the way that most boomers were taught to address their food and health. Certain boomer diet trends might make it easier for you to stay fit, especially if you're avoiding medications like GLP-1s (and the potential side effects of using GLP-1s). Fast food culture hasn't done much good for contemporary consumers. From oversized portions to sodium- and fat-laden menu items, [http://www.heatfluxclaw.com/index.php/User:SandyMccain7 MedicGLP Official] fast food can have a negative effect on your waistline and [https://khargharonline.com/author/asaloyd6790/ MedicGLP] overall health. Fast food was starting to find its way into communities across the United States just when the first boomers were coming of age. Yet rather than chowing on fast food items (which often have way more calories than you expect), most families at the time ate the bulk of their meals at home. Though this doesn't mean that every boomer entree, side dish, or dessert was healthier, it does mean that the food was generally made with fewer preservatives and chemicals. Preparing a meal at home gives the cook more control over the quality of a meal's ingredients, enabling them to include nutrient-rich foods that aren't ultraprocessed. Today's snacking culture is a far cry from what boomers experienced. It wasn't unusual for people to wait until standard meals like breakfast, lunch, and dinner to eat instead of having snacks all day. According to [https://realitysandwich.com/_search/?search=National%20Health National Health] and Nutrition Examinations Surveys data (via FoodNavigator-USA), in the late '70s, 40% of people in the U.S. 24 hours; three decades later, that only held true for 4% of respondents. Furthermore, more than half of the respondents admitted to having at least three snacks daily. This doesn't mean that snacking can't be good for you, but many people who snack between meals end up increasing their daily caloric intake more than they realize. A USDA chart from 2007-2008 indicates that the daily calorie value for snacks range from around 325 to 652 depending on a person's gender and age. By not snacking, you might be able to better maintain your weight without having to take any other steps. With that said, if you're on the road and absolutely have to have a snack, these are best snacks to munch on when you're on the go, according to a registered dietitian. Mixed with eating at home and only snacking sometimes, smaller portion sizes kept a lot of people leaner several decades ago. The portions that seem standard now weren't standard for boomers during their formative years. In fact, portion sizes have expanded between two- and five-fold since the mid-twentieth century, according to a 2021 editorial in the American Journal of Public Health. Research shows a correlation between increased portion sizes (sometimes referred to as "portion distortion") and health problems. Obesity research director Dr. [https://www.search.com/web?q=Marlene%20Schwartz Marlene Schwartz] told WebMD that one reason we can't physically handle the upsurge in food volume and calories is that we're not built for supersized portions. What can you do if you're in a "bigger portion" mindset?

ADA 81st Symposium: The Combination Of SGLT-2 Inhibitors And GLP-1 Receptor Agonists

2026-09-14T05:16:50Z

ElaineSams264: Created page with " Can a new potential combination treatment, using an SGLT-2 and a GLP-1 RA medication, mitigate cardiometabolic risk in people with diabetes? Dr. Vanita R. Aroda presented at the 2021 Scientific Sessions of the American Diabetes Association regarding mitigating cardiometabolic risk by combining sodium-glucose cotransporter-2 inhibitors (SGLT-2) and glucagon-like peptide-1 (GLP-1) receptor agonists. A literature review of recent publications of the individual and combi..."

Can a new potential combination treatment, using an SGLT-2 and a GLP-1 RA medication, mitigate cardiometabolic risk in people with diabetes? Dr. Vanita R. Aroda presented at the 2021 Scientific Sessions of the American Diabetes Association regarding mitigating cardiometabolic risk by combining sodium-glucose cotransporter-2 inhibitors (SGLT-2) and glucagon-like peptide-1 (GLP-1) receptor agonists. A literature review of recent publications of the individual and combined SGLT-2 inhibitors and GLP-1 RA drug classes helps to indicate the cardiorenal benefits outweigh the risks. In addition, the AHA heart disease and stroke statistics released a 2021 update related to cardiovascular risk factors, health behaviors, and contributory health factors on associated outcomes. The leading global risk factor for years of life lost from 1990 to 2019 is ischemic heart disease. In addition, the top risk factors for years of life lived with disability or injury globally and in the United States from 1990 to 2019 are high fasting prandial glucose and body mass index, which increased from 44.1% to 60.2%. The newly released statistics depict a significant demand for cardiorenal risk reduction due to diabetes and obesity. A randomized control trial published 2021 in the AHA Circulation by Dave CV et al. 2 diabetes after adding SGLT-2 inhibitors versus sulfonylureas to baseline GLP-1 RA therapy. The current study aims to establish if there are additional cardiovascular benefits from the combination therapy of SGLT-2 inhibitors and GLP-1 RA. The study included three datasets with 12,584 propensity score-matched pairs. The cardiovascular outcome of myocardial infarction and all-cause mortality was reduced by 24% in the SGLT-2 patients, and hospitalizations for heart failure were reduced by 35% compared to sulfonylureas patients. Thus, the addition of SGLT-2 to GLP-1 RA therapy resulted in more significant cardiovascular risk reduction. However, residual confounding among the therapeutic agents cannot be excluded. The EXSCEL trial by Clegg LE et al. SGLT-2 inhibitor treatment on mortality, cardiovascular, and [https://venturebeat.com/?s=renal%20outcomes renal outcomes] in type 2 diabetes patients. The 2019 open-label parallel study evaluated 575 patients in the SLGT-2 arm and 572 patients in the placebo arm. There was a reduction in the risk of major adverse cardiovascular events and a significant improvement in eGFR in the SGLT-2 group compared to the placebo. Thus, post hoc analysis supports the combination of GLP-1 and SGLT-2 therapy for possible benefits on cardiovascular outcomes. However, additional investigatory trials are necessary to draw a more robust conclusion. Aroda VR et al. 2019 that evaluated the efficacy, safety, and cardiovascular outcomes with subcutaneous semaglutide in treating type 2 [https://en.wiktionary.org/wiki/diabetes diabetes]. Data was review from SUSTAIN 1 to 7 phase 3 clinical trials with over 8,000 patients. Across all trials, semaglutide continuously demonstrated superior glycemic control, [http://yunseuljae.com/gnu5/bbs/board.php?bo_table=free&wr_id=337096 MedicGLP Online] weight loss, and reduction in cardiovascular risk compared to placebo and the standard of care. In addition, the safety profile of semaglutide was similar to the comparator except for an increased occurrence of GI effects, malignant neoplasm, cholelithiasis, elevated lipase, pancreatitis, and diabetic retinopathy. The adverse events must be taken into consideration when identifying a patient-specific therapeutic plan. The 2021 ADA pharmacologic approaches to glycemic treatment pathway are initially divided into indicators of high-risk/established ASCVD, CKD, [http://www.career4.co.kr/bbs/board.php?bo_table=ci_consulting&wr_id=913112 MedicGLP] HF, and A1C above individualized target. Patients with heart failure LVEF less than 45% are recommended to initiate an SGLT-2 inhibitor. High-risk ASCVD, CKD, promotion of weight loss, and minimized hypoglycemia indications can benefit from SGLT-2 inhibitors or GLP-1 RA for proven cardiorenal risk reduction, superior weight loss, and low incidence hypoglycemia in the clinical trials. Lastly, there is the monetary category where cost is a significant barrier to optimal care, where neither SGLT-2 nor GLP-1 RA is indicated. SGLT-2 and GLP-1 RA are among the more expensive anti-hyperglycemia medications. The 2020 JACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes discusses the lack of evidentiary studies regarding the concomitant use of SGLT-2 and GLP-1 RA with cardiovascular benefits. Regarding the personal benefits demonstrated in numerous trials, JACC 2020 determined that the use of both SGLT-2 and GLP-1 RA can be utilized if indicated. Due to high cost, monotherapy or dual treatment is not viable for many individuals. According to the gaps in evidence, study-based therapy use in insured patients in the United States with type 2 diabetes and atherosclerotic cardiovascular disease evaluates the underutilization of evidence-based therapies in 155,958 patients. 24.7% of patients used high-intensity statins, [https://doomsdaywrestling.wiki/index.php/User:RosemaryRow MedicGLP.com] 53.1% used ACE inhibitor or ARB, and 9.9% used either SGLT-2 inhibitor or GLP-1 RA. 2.7% of patients had insurance coverage for all three therapies. This study is a call to action for all involved parties to bridge the gap in care. The EXSCEL trial concluded that SGLT-2 to GLP-1 RA therapy resulted in more significant cardiovascular risk reduction. JACC 2020 determined that the use of both SGLT-2 and GLP-1 RA can be utilized if indicated. Due to high cost, neither monotherapy or dual treatment is viable for many individuals. Aroda VR. Combination Therapy with SGLT2i and GLP-1RA in Mitigating Cardiorenal Risk. American Diabetes Association mini-symposium. Science continues to prove that the old adage "you are what you eat" is profoundly true. This is because you have trillions of microorganisms living in your gut, which are directly responsible for nearly every aspect of your health. These microbes make up what’s called your "gut microbiota." They are especially influential in determining your likelihood of gaining excessive weight, becoming obese, and developing obesity-related diseases like diabetes, heart disease, and premature death. The gut microbiome (the expressed genes of your gut microbiota) plays a major role in your metabolism through energy production, storage, and expenditure. So, it’s no surprise that science has found a strong connection between gut microbiome imbalance and metabolic syndrome. Yikes! If you have the wrong mix of microbes, it could be making it tough for you to get your health on track! Did you know: Scientists can actually look at your gut microbiome composition and tell with 90% accuracy if you are obese or lean. That’s pretty impressive, isn’t it?

User:ElaineSams264

2026-08-14T05:08:22Z

ElaineSams264: Created page with "Hi! My name is Princess and I'm a 22 years old boy from Canada. Also visit my homepage ... [https://rentry.co/47026-glp-weight-loss-a-revolutionary-approach-to-obesity-management MedicGLP Online]"

Hi! My name is Princess and I'm a 22 years old boy from Canada. Also visit my homepage ... [https://rentry.co/47026-glp-weight-loss-a-revolutionary-approach-to-obesity-management MedicGLP Online]